Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.45 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.45 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.45 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.45 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.45 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.45 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.39 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.37 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.36 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | ABL2 | P42684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216027 | 0.99 | MAP4K4 (0.46) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL12233232 | 0.87 | SYK (0.43) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL2443460 | 0.86 | MAPK14 (0.44) | MAP4K4ABL1NTRK1FYNLYN | |
| Hydrochloric Acid SCHEMBL3775833 | 0.83 | MAP4K4 (0.52) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL378727 | 0.83 | SYK (0.43) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL9967319 | 0.82 | MAP4K4 (0.45) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL378875 | 0.82 | MAP4K4 (0.53) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL378778 | 0.81 | HTR2A (0.49) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL2448382 | 0.81 | HTR2A (0.54) | MAP4K4ABL1NTRK1FYNLYN | |
| Hydrochloric Acid SCHEMBL2450168 | 0.80 | MAP4K4 (0.40) | MAP4K4ABL1NTRK1FYNLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981851-B1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| CN-101415685-B | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC | 2011-08-24 | — | — | CN | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| CN-101415685-A | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | CN | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| EP-1981851-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | MAP3K1, MAP3K19, MAP3K20 | ABL1 28/4885NTRK1 807/4885RET 143/4885 |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | MAP3K19, MAP3K2, MAP3K20 | ABL1 28/4885NTRK1 600/4885RET 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.